AUTHOR=Li Lingzhi , Fang Zhifeng , Lee Yuan-kun , Zhao Jianxin , Zhang Hao , Peng Huaiming , Zhang Yulong , Lu Wenwei , Chen Wei 

TITLE=Efficacy and Safety of Lactobacillus reuteri CCFM1040 in Allergic Rhinitis and Asthma: A Randomized, Placebo-Controlled Trial

JOURNAL=Frontiers in Nutrition

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.862934

DOI=10.3389/fnut.2022.862934

ISSN=2296-861X

ABSTRACT=The coexistence of allergic rhinitis (AR) and asthma reinforces the concept of ‘‘one airway, one disease’’, which has prompted the exploration for a single intervention to treat both diseases. Our previous in vivo studies showed that Lactobacillus reuteri CCFM1040 (CCFM1040) was an inhibitor of the commen mechanism of AR and asthma. This study presented a randomized and placebo-controlled trial to investigated the clinical effects of CCFM1040 on both diseases. The total symptom score (TSS), the quality of life (QoL), and the modulation in gut microbiota of AR patients, the Asthma Control and Test (ACT) of asthma patients, and the safety of both AR and asthma were measured. In AR patients, CCFM1040 numerically decreased TSS, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), 3 nasal scores in TSS (nasal congestion, watery eyes, and rhinorrhea), and sleep, and significantly improved (P = 0.014) non-nose/eye symptoms. The ACT score was numerically increased in asthma patients (from partially controlled to well controlled). Significant microbial (from class level to genus level) and metabolic differences (P < 0.05) were found in patients with AR. No adverse reactions were observed. No effect on the blood and urine routine indexes. CCFM1040 have a potential benefit on both diseases. Further studies based on these findings will help to optimize the management of AR and asthma.